NL-OMON46021WithdrawnPhase 2
A Randomized Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects with Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT). - FUSION HR MDS/ELDERLY AML 001 STUDY
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Withdrawn
- Sponsor
- Celgene Corporation
- Enrollment
- 40
Study Overview
Brief Summary
Trial never started
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •For both cohorts:
- •1. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
- •2. Have an ECOG performance status of 0, 1, or 2 (Appendix E).
- •3. Female subjects of childbearing potential may participate, providing they meet the following conditions:
- •a. Have 2 negative pregnancy tests as verified by the Investigator prior to starting any IP therapy: serum pregnancy test at screening and negative serum or urine pregnancy test (Investigator's discretion) within 72 hours prior to starting treatment with IP (Cycle 1, Day 1). They must agree to ongoing pregnancy testing during the course of the study (before beginning each subsequent cycle of treatment), and after the last dose of any IP. This applies even if the subject practices complete abstinence from heterosexual contact.
- •b. Agree to practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to the use of a highly effective method of contraception from 28 days prior to starting durvalumab or azacitidine, and must agree to continue using such precautions while taking durvalumab or azacitidine (including dose interruptions) and for up to 90 days after the last dose of durvalumab or azacitidine. Cessation of contraception after this point should be discussed with a responsible physician.
- •c. Agree to abstain from breastfeeding during study participation and for at least 90 days after the last dose of IP.
- •d. Refrain from egg cell donation while taking durvalumab and for at least 90 days after the last dose of durvalumab.
- •4. Male subject must:
- •a. Either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis) or agree to avoid fathering a child, to use highly effective methods of contraception, to use male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy) from starting dose of IP (Cycle 1 Day 1), including dose interruptions through 90 days after receipt of the last dose of durvalumab or azacitidine.
- •b. Refrain from semen or sperm donation while taking IP and for at least 90 days after the last dose of IP.;More inclusion criteria can found in the protocol version 17Nov2015 on page 47.
Exclusion Criteria
- •For both cohorts:
- •1. Prior hematopoietic stem cell transplant.
- •2. Considered eligible for hematopoietic stem cell transplant (allogeneic or autologous) at the time of signing the ICF.
- •3. Prior exposure to azacitidine, decitabine or prior exposure to the investigational oral formulation of decitabine, or other oral azacitidine derivative.
- •4. Inaspirable bone marrow.
- •5. Use of any of the following within 28 days prior to the first dose of IP:
- •· Thrombopoiesis-stimulating agents (eg, romiplostim, eltrombopag, Interleukin-11)
- •· Any hematopoietic growth factors (ESAs and other RBC hematopoietic growth factors (eg, Interleukin-3)
- •· Any investigational agents within 28 days or 5 half-lives (whichever is longer) of initiating study treatment ;More exclusion criteria can found in the current protocol version, and clinical trial application form.
Investigators
Similar Trials
Withdrawn
Phase 2
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain MetastasisNL-OMON49456Array Biopharma Inc.10
Withdrawn
Phase 2
A Randomized, Open-Label Phase 2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma.NL-OMON55480Eli Lilly1
Withdrawn
Phase 2
A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A (AGN 151607) Injections into the Epicardial Fat Pads to Prevent Post-Operative Atrial Fibrillation in Patients Undergoing Open-Chest Cardiac SurgeryNL-OMON55701Allergan Ltd.30
Withdrawn
Phase 2
A PHASE I/II, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF COBIMETINIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH PREVIOUSLY TREATED SOLID TUMORSsolide tumorenabnormal cellular and tumor growth in an organSolid tumorsNL-OMON44717F. Hoffmann-La Roche Ltd.2
Withdrawn
Phase 2
A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)NL-OMON49921ektar Therapeutics6